Abstracts tagged "Antiphospholipid syndrome and genetics"

Abstract Number: 1961 • 2016 ACR/ARHP Annual Meeting
Identification of Novel Genetic Susceptibility Loci in Primary Antiphospholipid Syndrome
Elizabeth Gensterblum¹, Travis Hughes², Manuel Martínez-Bueno³, Maria Orietta Borghi⁴, Guillermo J. Pons-Estel⁵, Gerard Espinosa⁶, Alexandra Zhernakova⁷, Cisca Wijmenga⁸, Ricard Cervera⁵, Pier Luigi Meroni⁹, Marta Alarcón-Riquelme^3,10 and Amr Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, ³Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁴University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁸Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁹Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milan, Italy, ¹⁰Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with incompletely understood etiology, characterized by recurrent thrombosis and pregnancy complications. We conducted this study to understand…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].